# Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma

> **NCT06485739** · PHASE4 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 20 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Irinotecan liposomes combined with cisplatin/carboplatin

## Key facts

- **NCT ID:** NCT06485739
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485739, "Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT06485739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*